Patents by Inventor Paolo Innocenti
Paolo Innocenti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240417388Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: August 8, 2024Publication date: December 19, 2024Inventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti
-
Patent number: 12110286Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: GrantFiled: May 25, 2018Date of Patent: October 8, 2024Assignees: Cancer Research Technology Limited, The Institute of Cancer ResearchInventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti
-
Publication number: 20240279425Abstract: Industrial depolymerization process of polyethylene terephthalate (PET) contained in artificial, natural and mixed dimethyl terephthalate (DMT) fibres by a first depolymerization of the PET in the presence of ethylene glycol and a catalyst (preferably sodium carbonate) to bis hydroxyethylene terephthalate (BHET), and subsequent transesterification of BHET solutions from the pressing of said artificial or natural fibres and from the washing of the same fibres. This process is characterized in that: in step a) the weight ratio of PET-containing fibres to ethylene glycol is between 0.3 and 4, preferably between 1.2 and 1.5; step b) comprises a step b-1) of pressing the final mixture and a step b-2) of washing the fibres from b1) with methanol or with the post-crystallization recovery solution of DMT, and in step c) the transesterification is carried out on the BHET liquid solution from the pressing b-1) and on that also containing methanol from washing the fibres of step b-2).Type: ApplicationFiled: July 13, 2022Publication date: August 22, 2024Inventors: Davide MOSCATELLI, Giuseppe STORTI, Flavio TOLLINI, Gianmarco POLOTTI, Lorenzo BRIVIO, Paolo INNOCENTI
-
Patent number: 11897877Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: May 13, 2021Date of Patent: February 13, 2024Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20220402912Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: May 13, 2021Publication date: December 22, 2022Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 11046688Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: October 10, 2019Date of Patent: June 29, 2021Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20210147382Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: May 25, 2018Publication date: May 20, 2021Inventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti
-
Publication number: 20200165241Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: October 10, 2019Publication date: May 28, 2020Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 10479788Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: January 8, 2018Date of Patent: November 19, 2019Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 10399974Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: January 3, 2018Date of Patent: September 3, 2019Assignee: Cancer Research Technology LimitedInventors: Hannah Woodward, Paolo Innocenti, Sebastien Naud, Julian Blagg, Swen Hoelder
-
Publication number: 20180194761Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 3, 2018Publication date: July 12, 2018Inventors: Hannah Woodward, Paolo Innocenti, Sebastien Naud, Julian Blagg, Swen Hoelder
-
Publication number: 20180141944Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 8, 2018Publication date: May 24, 2018Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 9902721Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: February 27, 2015Date of Patent: February 27, 2018Assignee: Cancer Research Technology LimitedInventors: Hannah Woodward, Paolo Innocenti, Sebastien Naud, Julian Blagg, Swen Hoelder
-
Patent number: 9890157Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: April 6, 2016Date of Patent: February 13, 2018Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 9834552Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: April 6, 2016Date of Patent: December 5, 2017Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20160362409Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: February 27, 2015Publication date: December 15, 2016Inventors: Hannah WOODWARD, Paolo INNOCENTI, Sebastien NAUD, Julian BLAGG, Swen HOELDER
-
Patent number: 9409907Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: September 9, 2013Date of Patent: August 9, 2016Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20160222009Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 6, 2016Publication date: August 4, 2016Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20160220570Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 6, 2016Publication date: August 4, 2016Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20150239884Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: September 9, 2013Publication date: August 27, 2015Applicant: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash